Literature DB >> 8050903

[Chondroid syringoma. Immunohistologic indications of myoepithelial differentiation].

M Wilk1, D Klesper, M Uerlich, E Biwer, R Wimheuer.   

Abstract

Chondroid syringoma belongs to the group of so-called mixed tumors, like pleomorphic adenomas of the lacrimal and salivary glands. The histogenesis of this tumour is still disputed, in particular with respect to its stromal component. The distribution of cytokeratins (CKs), CEA, EMA, vimentin, S-100 protein, desmin and actin [alpha-smooth muscle actin (alpha-SMA)] was investigated by immunohistological examination of paraffin sections from a chondroid syringoma of the apocrine type. The neoplastic formations have been classified into tubuloalveolar structures, solid nests/aggregations and stromal cells of varying morphology. The inner-most cells of tubuloalveolar structures were characterized by marked expression of CKs (KL1 and MNF116), CEA and EMA, while in the outer ones there was moderate expression of vimentin, S-100 was expressed to a lesser extent and KL1, weakly but there was marked and consistent expression of MNF116. Whereas the solid nests expressed vimentin, S-100 protein, MNF116 markedly and KL1 weakly, the stromal cells were consistently positive for vimentin, S-100 protein and, focally, CKs and alpha-SMA. Anti-alpha-SMA specifically detects myoepithelial cells. In addition, the partly overlapping immunoreactivity of the intermediate filaments, membrane proteins and proteins in the different structures may indicate a common clonal origin of all neoplastic cells in chondroid syringoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050903     DOI: 10.1007/s001050050077

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  2 in total

1.  [Mixed tumor of the skin].

Authors:  M Zirbs; A Konstantinow; M Ziai; K Brockow; R Hein; J Ring
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

Review 2.  [Skin adnexal and salivary gland neoplasms. Similarities and differences of selected patients].

Authors:  T Mentzel
Journal:  Pathologe       Date:  2004-02       Impact factor: 1.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.